MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Total Liabilities
Everything the company owes to creditors and other parties.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Total Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total liabilities rises 120.7% from a year ago
Total liabilities stood at $27.67M at the end of Q3 FY2026, up 120.7% from a year earlier and up 4.9% from the prior quarter. Over 3 fiscal years it compounded at -43.4% a year.
Context
- Total liabilities amounted to 5.5% of total assets at the end of Q3 FY2026, up 2.4 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +120.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 15.92M USD
- Year-over-year change
- +43.5%
- 3-year CAGR
- -43.4%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.92M | +43.5% |
| FY2024 | 2024-12-31 | 11.09M | -92.9% |
| FY2023 | 2023-12-31 | 156.65M | +78.6% |
| FY2022 | 2022-12-31 | 87.7M | — |
Total Liabilities vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +120.7% is the 4th highest of 8, against a peer median of +14.4%.
- Total liabilities amounts to 5.5% of total assets for MBX, versus a peer median of 30.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | €926.73M EUR | -30.3% | +21.0% | 38.2% | |
| Mar 2026 | $379M USD | +8.1% | +7.3% | 96.7% | |
| Sep 2026 | $241.59M USD | +14.4% | +21.1% | 54.5% | |
| Jun 2026 | $113.58M USD | +250.7% | +48.9% | 21.8% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $92.95M USD | — | — | 7.7% |
| Mar 2026 | $51.64M USD | +242.0% | +36.5% | 15.4% | |
| Mar 2026 | $30.57M USD | +299.9% | +43.7% | 11.4% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $27.67M USD | +120.7% | -43.4% | 5.5% |
| Mar 2026 | $27.67M USD | +5.1% | +11.8% | 59.6% | |
| Peer median (excluding MBX) | — | +14.4% | +21.1% | 30.0% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.